불면증은 현재 국제 수면장애 분류(제3판, ICSD-3)와 정신장애 진단 및 통계편람(제5판, DSM-5)에 명시되어 있으며, 충분한 수면 기회와 환경이 있음에도 불구하고 환자가 보고하는 수면 진입 장애 또는 수면 유지 장애로 정의됩니다. 이 증상에는 잦은 각성, 각성 후 수면 복귀의 어려움, 또는 너무 일찍 깨어나서 수면 복귀가 불가능하여 낮 동안 신체적, 인지적 기능이 손상되는 증상이 포함됩니다. 이러한 증상은 단독으로 발생하거나 동시에 발생할 수 있으며, 그 증상은 시간이 지남에 따라 변화합니다.
주요 7개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 불면증 시장 규모는 예측 기간 동안 꾸준한 성장세를 보일 것으로 예상됩니다. 이러한 성장의 원동력은 주로 EUSOL Biotech의 SM-1, Taisho Pharmaceutical의 vornorexant, Imbrium Therapeutics의 sunobinop, Vanda Pharmaceuticals의 Hetlioz 등 기대되는 파이프라인 제품들의 등장이 주요 요인으로 작용할 것입니다. 하지만 다가오는 특허 만료가 시장 성장을 억제할 것으로 예상됩니다.
본 보고서는 주요 7개국의 불면증 시장을 조사하여 시장 개요와 함께 불면증 치료제 및 후기 파이프라인 후보물질에 대한 시장 전망 등을 제공합니다.
목차
제1장 서문
제2장 주요 요약
제3장 질병 개요
- 불면증 개요
- 불면증 SWOT 분석
- 불면증 병태생리학
- 불면증 분류
제4장 역학
제5장 현재 치료 선택사항
- 치료 패러다임
- 현재 치료 선택사항
- 제품 프로파일 : 벤조디아제핀(예: 에스타졸람, 테마제팜, 플루라제팜)
- 제품 프로파일 : Z-Drugs (잘레플론, 졸피뎀, 조피클론, 에스조피클론)
- 제품 프로파일 : 멜라토닌 수용체 작용제(라멜테온 및 멜라토닌 ER)
- 제품 프로파일 : 저용량 항우울제(독세핀, 트라조돈, 트리미프라민)
- 제품 프로파일 : 항히스타민제(예: 디펜히드라민, 프로메타딘, 하이드록시딘)
- 제품 프로파일 : 가바펜티노이드(예: 가바펜틴, 프레가발린)
- 제품 프로파일 : Merck & Co의 Belsomra(수보렉산트)
- 제품 프로파일 : Eisai의 Dayvigo(렘보렉산트)
- 제품 프로파일 : Idorsia의 Quiviviq (Daridrexant)
제6장 미충족 수요와 기회
- 불면증의 미충족 수요
- 유효성이 향상된 새로운 치료 옵션
- 불면증 치료에 대한 의사 의식 향상
- CBT-i로의 환자 액세스 향상
제7장 연구개발 전략
- 불면증의 임상시험 설계 동향
- 불면증의 거래 동향
제8장 파이프라인 평가
- 불면증 파이프라인 개요
- 불면증에 대한 후기 파이프라인 약제
- 제품 프로파일 : EUSOL Biotech SM-1
- 제품 프로파일 : Taisho Pharmaceutical의 Vornorexant
- 제품 프로파일 : Imbrium Therapeutics의 Sunobinop
- 제품 프로파일 : Vanda Pharmaceutical의 Hetlioz (tasimelteon)
- 불면증 : 임상시험(제II/III상) 개요
제9장 시장 전망
- 불면증 시장 예측
- 시장 성장 촉진요인과 억제요인
제10장 부록
제11장 문의
ksm
Abstract
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the insomnia market through 2032.
Insomnia, currently represented in the International Classification of Sleep Disorders (Third Edition; ICSD-3) and the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition; DSM-5), is defined as patient-reported difficulty with sleep initiation or sleep maintenance, despite adequate opportunity and circumstances for sleep. It can include frequent awakenings, difficulty returning to sleep after awakening, or awakening too early with the inability to return to sleep, which impair physical and cognitive function during the daytime. These symptoms may occur in isolation or together, and the presentation may vary over time.
GlobalData anticipates the global insomnia market-which, for the purpose of this report, comprises seven major pharmaceutical markets (7MM: US, France, Germany, Italy, Spain, UK, Japan)-will experience steady growth during the forecast period. This growth will be driven primarily by the anticipated arrival of pipeline products: EUSOL Biotech's SM-1, Taisho Pharmaceutical's vornorexant, Imbrium Therapeutics' sunobinop, and Vanda Pharmaceuticals' Hetlioz. Nevertheless, looming patent expiries are expected to curtail market growth.
This model covers the market forecast for insomnia therapies and late-stage pipeline candidates. The base year of this model is 2022 and the forecast period is 2022-32.
Scope
- Overview of insomnia, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized insomnia treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the insomnia therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for insomnia treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global insomnia therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global insomnia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global insomnia therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Table of Contents
1. Preface
- 1.1. Contents
- 1.2. Abbreviations
- 1.3. Related Reports
2. Executive Summary
3. Disease Overview
- 3.1. Overview of Insomnia
- 3.2. Insomnia SWOT Analysis
- 3.3. Pathophysiology of Insomnia
- 3.4. Classification of Insomnia
4. Epidemiology
- 4.1. Total Prevalent Cases of Insomnia, Both Sexes, Ages ≥15 Years, 2022-32
- 4.2. Age-Specific Trends in the Total Prevalent Cases of Insomnia, Both Sexes, 2022
- 4.3. Sex-Specific Total Prevalent Cases of Insomnia, Both Sexes, Ages ≥15 Years, 2022
- 4.4. Sex-Specific Total Prevalent Cases of Acute Insomnia, Ages ≥15 Years, 2022
- 4.5. Sex-Specific Total Prevalent Cases of Chronic Insomnia, Ages ≥15 Years, 2022
- 4.6. Sources and Methodology for Acute and Chronic Insomnia Prevalence
- 4.7. Sources and Methodology - Total Prevalent Cases of Acute and Chronic Insomnia
5. Current Treatment Options
- 5.1. Treatment Paradigm
- 5.2. Current Treatment Options
- 5.3. Product Profile: Benzodiazepines (e.g., estazolam, temazepam, flurazepam)
- 5.4. Product Profile: Z-Drugs (zaleplon, zolpidem, zopiclone, eszopiclone)
- 5.5. Product Profile: Melatonin Receptor Agonists (ramelteon and melatonin ER)
- 5.6. Product Profile: Low-Dose Antidepressants (doxepin, trazodone, trimipramine)
- 5.7. Product Profile: Antihistamines (e.g., diphenhydramine, promethazine, hydroxyzine)
- 5.8. Product Profile: Gabapentinoids (e.g., gabapentin and pregabalin)
- 5.9. Product Profile: Merck & Co's Belsomra (suvorexant)
- 5.10. Product Profile: Eisai's Dayvigo (lemborexant)
- 5.11. Product Profile: Idorsia's Quviviq (daridorexant)
6. Unmet Needs and Opportunities
- 6.1. Unmet Needs in Insomnia
- 6.2. New Therapeutic Options with Improved Efficacy
- 6.3. Improved Physician Awareness of Insomnia Treatments
- 6.4. Improved Patient Access to CBT-i
7. R&D Strategies
- 7.1. Trends in Clinical Trial Design in Insomnia
- 7.2. Trends in Deal-Making in Insomnia
8. Pipeline Assessment
- 8.1. Insomnia Pipeline Overview
- 8.2. Late-Stage Pipeline Agents for Insomnia
- 8.3. Product Profile: EUSOL Biotech's SM-1
- 8.4. Product Profile: Taisho Pharmaceutical's Vornorexant
- 8.5. Product Profile: Imbrium Therapeutics's Sunobinop
- 8.6. Product Profile: Vanda Pharmaceuticals's Hetlioz (tasimelteon)
- 8.7. Insomnia: Clinical Trials (Phase II/III) Overview
9. Market Outlook
- 9.1. Insomnia Market Forecast
- 9.2. Market Drivers and Barriers
10. Appendix
- 10.1. Primary Research: KOL Information
- 10.2. Bibliography
- 10.3. About the Authors
11. Contact Us
